Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
Regulus Therapeutics Inc. (RGLS)
Sector: Healthcare; Industry: Biotechnology

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-17 Aker Christopher Ray Sr. VP & General Counsel Sell 860 $0.89 $765 No
2021-02-16 Hagan Joseph P President and CEO Sell 4,144 $1.72 $7,128 No
2021-02-16 Aker Christopher Ray Sr. VP & General Counsel Sell 828 $1.72 $1,424 No
2021-02-16 Hagan Joseph P President and CEO Sell 4,144 $1.72 $7,128 No
2020-12-04 Walker Paul Edward 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Sonsini Peter W. 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 SANDELL SCOTT D 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 MAKOWER JOSHUA 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Makhzoumi Mohamad 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Florence Anthony A. Jr. 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Chang Carmen 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Behbahani Ali 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 BASKETT FOREST 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-12-04 Growth Equity Opportunities V, LLC 10%-Owner Buy 4,398,602 $0.62 $2,735,930 Yes
2020-11-16 Aker Christopher Ray Sr. VP & General Counsel Sell 876 $0.52 $456 No
2020-11-16 Hagan Joseph P President and CEO Sell 6,094 $0.52 $3,176 No
2020-08-14 Hagan Joseph P President and CEO Sell 4,245 $0.60 $2,568 No
2020-08-14 Aker Christopher Ray Sr. VP & General Counsel Sell 872 $0.60 $528 No
2020-05-15 Hagan Joseph P President and CEO Sell 4,426 $0.63 $2,774 No
2020-05-15 Aker Christopher Ray Sr. VP & General Counsel Sell 909 $0.63 $570 No
2020-02-18 Hagan Joseph P President and CEO Sell 4,324 $0.83 $3,591 No
2020-02-18 Aker Christopher Ray Sr. VP & General Counsel Sell 888 $0.83 $737 No
2020-01-02 Hagan Joseph P President and CEO Sell 8,345 $0.97 $8,067 No
2020-01-02 Aker Christopher Ray Sr. VP & General Counsel Sell 2,239 $0.97 $2,164 No
2019-11-14 Aker Christopher Ray Sr. VP & General Counsel Sell 833 $0.64 $533 No
2019-11-14 Hagan Joseph P President and CEO Sell 5,838 $0.64 $3,736 No
2019-10-01 Aker Christopher Ray Sr. VP & General Counsel Sell 2,346 $0.68 $1,602 No
2019-10-01 Hagan Joseph P President and CEO Sell 8,743 $0.68 $5,969 No
2019-08-15 Hagan Joseph P President and CEO Sell 4,375 $0.55 $2,409 No
2019-08-15 Aker Christopher Ray Sr. VP & General Counsel Sell 899 $0.55 $495 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.